LUND, Sweden, Feb. 10, 2020 /PRNewswire/ -- Immunovia invites to a teleconference (in English) for investors, analysts and media on Friday, February 14th, 2020 at 8:30 am CET. Immunovia will publish the company's Full Year 2019 report on February 14th, 2020 at 8:00 am CET.
Mats Grahn, CEO will present Immunovia and comment on the interim report for the period Full Year 2019 Report followed by a Q&A session. Please call in a few minutes in advance.
To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator:
Dial-in numbers:
Sweden: +46-(0)-8-50-520-424
United States: +1-212-999-6659
Austria: +43-(0)-12530807
Germany: +49-(0)-30-3001-90612
Denmark: +45-3271-4573
Switzerland: +41-(0)-22-592-7103
Spain: +34-91-787-0777
Netherlands: +31-(0)-20-794-8426
Norway: +47-2156-3318
France: +33-(0)-1-7037-7166
United Kingdom (standard international access): +44-(0)-20-3003-2666
Conference code:
(To provide to the operator): Immunovia
Webcast:
https://channel.royalcast.com/webcast/immunovia/20200214_1/
There will be an MP3-file available at Immunovia's webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.
About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
The first product, IMMray PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q3 2020. When validated, IMMray PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
CONTACT:
For more information, please contact:
Julie Silber, Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/immunovia-ab/r/invitation-to-presentation-of-immunovia-s-full-year-report-2019-on-february-14--2020,c3031814
The following files are available for download:
https://mb.cision.com/Main/13121/3031814/1191309.pdf | Release |
